1
Return

Type 2 diabetes prevention across the life course

delete2026-08-10
delete0
PRE
AI
Y
Yiying Wang
J
Jennifer L Sargent
C
Chantal Mathieu
E
Elsa Vazquez Arreola
L
Leigh Perreault
R
Ruth J. F. Loos
L
Lee‐Ling Lim
L
Leontine Sandforth
R
Robert L. Hanson
S
Stephanie Kullmann
J
Julia Sbierski‐Kind
S
Sara Y. Brucker
M
Martin Hrabě de Angelis
F
Fabian J. Theis
A
Andrea Icks
D
Damon Mohebbi
N
Norbert Stefan
V
Viswanathan Mohan
T
Tiange Wang
H
Hubert Preißl
M
Michael Bergman
J
Jaakko Tuomilehto
M
Marie‐France Hivert
P
Paul W. Franks
A
Andreas L. Birkenfeld *
DOI:10.1038/s41591-026-04550-zdelete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Type 2 diabetes (T2D) prevention efforts have largely focused on intervening when dysglycemia is already established. We propose that T2D prevention be reframed around prediabetes remission, with preservation and restoration of normoglycemia as the optimal clinical goal. The transition from normoglycemia through increasing dysglycemia to T2D is progressive and cumulatively shaped by biological, behavioral and environmental exposures across the life course. Prediabetes (intermediate hyperglycemia) remission is an achievable, pragmatic and measurable prevention target. Here we provide a life-course risk architecture for T2D integrating developmental, transitional and contextual determinants, defining critical windows of amplified metabolic vulnerability and potential restoration of normoglycemia. Precision prevention should target mechanistic heterogeneity, with aligned interventions that remain scalable, affordable and adaptable across socioeconomic settings. Our framework identifies ten priorities in T2D prevention, moving beyond traditional approaches toward context-specific, actionable interventions capable of altering the natural history of disease early in the life course and restoring metabolic health. Rather than intervening when dysglycemia is established, prevention efforts should focus on prediabetes remission and restoration of normoglycemia. Here the authors call for a new agenda informed by mechanistic heterogeneity, a life-course risk architecture and scalable precision tools.

Journal

Nature Medicine cover
Nature Medicine
IF:
50
Papers:
1.4W
Citations:
13.4W

Organization

G
german center for diabetes research
Scholars:
84
Papers: 33
Citations: 0
H
Helmholtz Munich
Scholars:
359
Papers: 143
Citations: 58
S
shanghai jiao tong university
Scholars:
15.1W
Papers: 11.5W
Citations: 159
H
harvard pilgrim health care institute
Scholars:
64
Papers: 27
Citations: 0
Heinrich Heine University Düsseldorf cover
Heinrich Heine University Düsseldorf
Scholars:
696
Papers: 263
Citations: 2.8W
U
University of Tübingen
Scholars:
295
Papers: 122
Citations: 0
U
University of Helsinki
Scholars:
4.2K
Papers: 1.7K
Citations: 5.1W
I
imperial college london
Scholars:
8.3K
Papers: 3.8K
Citations: 0
L
Lund University
Scholars:
2.0K
Papers: 856
Citations: 5.1W
K
katholieke universiteit leuven
Scholars:
134
Papers: 66
Citations: 0
U
universiti malaya
Scholars:
3.5K
Papers: 1.5K
Citations: 0
U
University of Colorado School of Medicine
Scholars:
835
Papers: 370
Citations: 0
U
university of copenhagen
Scholars:
6.3K
Papers: 2.5K
Citations: 0
M
Madras Diabetes Research Foundation
Scholars:
562
Papers: 422
Citations: 684
Cited Papers

Cited Papers

Citing Papers

Citing Papers